Compare GSK plc (GSK) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| GSK | SGOV | |
|---|---|---|
Market Cap | $91.88B | $114.40B |
Volume | 7,730,529 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $100.72 |
52-Week Low | $43.24 | $100.28 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.47 with minimal daily price movement, reflecting its ultra-short-term Treasury bond focus. The technical picture shows bearish momentum with moving averages signaling caution, while oscillators remain neutral. Recent corporate actions include consistent dividend distributions around $0.30-0.31 per share through mid-2026.
As a Treasury bond ETF, SGOV offers low volatility and regular income but faces headwinds from rising interest rates. The fund provides exposure to short-term government debt with minimal credit risk, though higher yields elsewhere may pressure returns. Current bond market volatility creates both challenges and opportunities for short-term fixed income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
